This development-stage biopharmaceutical company, headquartered in Cambridge, Massachusetts, is dedicated to creating first-in-class immunomodulators that target the interaction between TCR and Nck, providing specific control over T-cells for the treatment of a wide range of autoimmune and inflammatory diseases. Their drugs eliminate harmful foreign pathogens while being tolerant of self-tissues and organs, allowing doctors to treat both the symptoms and the underlying disease with fewer side effects. Founded in 2013, Artax Biopharma is committed to developing the next generation of drugs that have the potential to revolutionize the treatment of autoimmune and inflammatory diseases.